Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8114MR)

This product GTTS-WQ8114MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8114MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3058MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ15219MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ7177MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ10673MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ8319MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ14414MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ13199MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ7878MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-2398852
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW